Designing a Multi-Region Stability Study: Best Practices
Pharmaceutical companies planning global submissions must ensure that their stability studies address the regulatory expectations of multiple regions simultaneously. This process—known as designing a multi-region stability study—requires careful planning, compliance with ICH guidelines, and incorporation of climatic zone-specific requirements. Failure to align protocols across agencies like the USFDA, EMA, WHO, CDSCO, and ANVISA can result…
Read More “Designing a Multi-Region Stability Study: Best Practices” »